
|Videos|December 18, 2020
Safety and efficacy of KPI-121 0.25% for DED treatment
Author(s)David Hutton
Preeya Gupta, MD, discusses the results of a study evaluating the safety and efficacy of KPI-121 0.25% for the treatment of dry eye disease.
Advertisement
Preeya Gupta, MD, discusses the results of a study evaluating the safety and efficacy of KPI-121 0.25% — a nanoparticle ophthalmic suspension of loteprednol etabonate — for the treatment of
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FDA approves phentolamine ophthalmic solution 0.75% (Ryzumvi) for presbyopia
2
Alvotech files first known aflibercept 8 mg biosimilar with EMA
3
Duravyu misses noninferiority end point in phase 3 LUCIA wet AMD trial
4
FDA approves subcutaneous Enspryng for TED
5

















